Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis

1Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China
2Department of Liver Diseases, Ma’anshan Fourth People’s Hospital, Ma’anshan, 243031, China
3Department of Molecular & Cellular Physiology, Shinshu University School of Medicine, 3900803, Japan
4School of Public Health, Hangzhou Medical College, Hangzhou, 311300, China
5Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, China

ABSTRACT

Background. To investigate the clinical outcome of patients with infective endocarditis (IE) during and after outpatient parenteral antimicrobial treatment (OPAT), and to further clarify the safety and efficacy of OPAT for IE patients.

Methods. Through December 20, 2021, a total of 331 articles were preliminarily searched in Pubmed, Web of Science, Cochrane Library and Embase, and 9 articles were eventually included in this study.

Results. A total of 9 articles comprising 1,116 patients were included in this study. The overall mortality rate of patients treated with OPAT was 0.04 (95% CI, 0.02-0.07), that means 4 deaths per 100 patients treated with OPAT. Separately, mortality was low during the follow-up period after OPAT treatment, with an effect size (ES) of 0.03 (95% CI, 0.02-0.07) and the mortality of patients during OPAT treatment was 0.04 (95% CI, 0.01-0.12). In addition, the readmission rate was found to be 0.14 (95% CI, 0.09-0.22) during the follow-up and 0.18 (95% CI, 0.08-0.39) during treatment, and 0.16 (95% CI, 0.10-0.24) for patients treated with OPAT in general. Regarding the relapse of IE in patients, our results showed a low overall relapse rate, with an ES of 0.03 (95% CI, 0.01-0.05). In addition, we found that the incidence of adverse events was low, with an ES of 0.26 (95% CI, 0.19-0.33).

Conclusion. In general, the incidence of adverse events and mortality, readmission, and relapse rates in IE patients treated with OPAT are low both during treatment and follow-up period after discharge, indicating that OPAT is safe and effective for IE patients. However, our study did not compare routine hospitalization as a control group, so conclusions should be drawn with caution. In order to obtain more scientific and rigorous conclusions and reduce clinical risks, it is still necessary to conduct more research in this field and improve the patient selection criteria for OPAT treatment, especially for IE patients. Finally, clinical monitoring and follow-up of OPAT-treated patients should be strengthened.

Keywords: outpatient parenteral antimicrobial therapy (OPAT), infective endocarditis (IE), meta-analysis

Eficacia y seguridad del tratamiento antibiótico domiciliario endovenoso en pacientes con endocarditis infecciosa: un metaanálisis

RESUMEN

Introducción. Investigar el resultado clínico de los pacientes con endocarditis infecciosa (EI) durante y después del tratamiento antibiótico domiciliario endovenoso (TADE), y determinar la seguridad y eficacia del TADE para los pacientes con EI.

Métodos. Hasta el 20 de diciembre de 2021, se realizaron búsquedas preliminares en un total de 331 artículos en Pubmed, Web of Science, Cochrane Library y Embase, y finalmente se incluyeron 9 artículos en este estudio.

Resultados. Se incluyeron un total de 9 artículos con 1.116 pacientes. La tasa de mortalidad global de los pacientes tratados con TADE fue de 0.04 (IC95%: 0.02-0.07), lo que significa 4 muertes por cada 100 pacientes tratados con TADE. Por separado, la mortalidad fue baja durante el periodo de seguimiento después del tratamiento con TADE, con un tamaño del efecto (TE) de 0.03 (IC95%: 0.02-0.07) y la mortalidad de los pacientes durante el tratamiento con TADE fue de 0.04 (IC95%: 0.01-0.12). Además, se encontró que la tasa de readmisión fue de 0.14 (IC95%: 0.09-0.22) durante el seguimiento y de 0.18 (IC95%: 0.08-0.39) durante el tratamiento, y de
INTRODUCTION

Infective endocarditis (IE) is a serious infectious disease with significant associated mortality, morbidity and results in considerable medical burden to patients. The common pathogenic bacteria causing IE include Staphylococcus spp (Staphylococcus aureus predominates), Streptococcus spp and Enterococcus spp, and by other less common organisms such as the HACEK Gram-negative bacilli (Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae) and fungi (Candida spp, Aspergillus spp) [1-4]. The annual incidence of IE is 3-7 cases per 100,000 population, and, despite advances in diagnosis and treatment, mortality in IE patients remains high, with a reported mortality rate of 15-20% in hospital and about 40% per year during follow-up [5-7]. Patients with IE may experience serious complications early, including arterial embolism, infectious metastasis to different organs, and the development of acute heart failure, all of which are major causes of death and the most common cause of emergency valve surgery [7]. Treatment of this complex and serious disease is based on the use of appropriate antibiotics, early detection of complications, and cardiac surgery when appropriate [7].

Outpatient parenteral antimicrobial therapy (OPAT) refers to the monitored administration of parenteral antibiotics in non-inpatient or outpatient settings (e.g., clinic, home, office), and besides shortening the duration of hospitalization, a major reason for OPAT use that it is a strategy to conserve antibiotic expenditures [1,8]. OPAT can be used to treat a wide variety of infections, including skin and soft tissue infections, bone and joint infections, endocarditis, gram-positive bacteremia, increasing drug-resistant gram-negative infections, and other specific fungal infections (e.g., cryptococcosis, candidiasis), viral infections (e.g., cytomegalovirus), or protozoa infections (e.g., Leishmania) [8]. Numerous previous studies have shown that OPAT is safe and effective for the treatment of IE [9-17]. A study by Kortajarena et al. reported that only 1 in 194 patients diagnosed with IE died during follow-up after medication [9]. In addition, a prospective cohort study by Perica et al. found that the mortality of patients in the OPAT group was significantly lower than that in the control group during the follow-up period of one year after discharge [10]. OPAT is commonly used to consolidate antimicrobial therapy after initial hospitalization and, despite its benefits, it may increase clinical risk due to reduced clinical supervision and monitoring [11]. In addition, studies indicate that even with careful patient selection and a multidisciplinary team-driven treatment plan, the use of potentially toxic antimicrobials and the duration of treatment mean that complications, including treatment failure, and readmission of some patients managed through OPAT are inevitable [11].

Considering the therapeutic effect of OPAT on IE patients and the possible increased clinical risk, and no meta-analysis has been found, we conducted this study to explore the clinical outcome of IE patients after OPAT treatment, and further clarify the safety and efficacy of OPAT in IE patients.

MATERIAL AND METHODS

Search strategy. We searched scientific and medical databases Pubmed, Web of Science, Embase and Cochrane Library for relevant literature, and restricted the language to English. Search terms included “OPAT”, “outpatient parenteral antimicrobial therapy (OPAT)”, “infective endocarditis (IE)”. Through December 20, 2021, 331 studies were retrieved. After the initial screening, the full text was further read to select the studies that could be included. 331 studies were obtained in the preliminary retrieval. Among which, 179 were duplicates, 113 were irrelevant or contained no relevant data, 26 were reviews or conference abstracts, 4 were letters or case reports and were excluded, ultimately including a total of 9 articles (Figure 1). The selection of studies was carried out by two researchers. If the studies selected by them were inconsistent, they would check the studies selected by the other side and focus on the discussion to determine the final literature that could be included.

Inclusion and exclusion criteria. Inclusion criteria were as follows: i) P (patient): the subjects were patients diagnosed with IE; ii) I (intervention): outpatient parenteral antimicrobial therapy; iii) O (outcome): readmission for any cause, all-cause mortality, IE relapse, and adverse events during the treatment or follow-up period.

Exclusion criteria were as follows: i) irrelevant to the research direction or without relevant data; ii) reviews or meeting abstracts; iii) duplicate studies; iv) letters or case reports.

Data Extraction. In this study, the data collected included: the name of the first author, year of publication, total number of subjects, number of IE deaths, readmission recurrence, and number of adverse events during OPAT the treatment and follow-up period.
Quality assessment of included studies.

a) Quality assessment of 5 cohort studies [9,10,12,13,15]:

The Newcastle-Ottawa Scale (NOS) was used to perform quality assessment (Table 1). The results revealed that 3 cohort studies showed 9 points, and 2 cohort studies showed 7 points. The articles by Htin et al [12] and Pajarón et al [13] did not describe the results during follow-up period.

b) Quality assessment of 4 retrospective analysis studies [11,14,16,17]:

The Joanna Briggs Institute critical capital checklist for students reporting progress data [18] was used to evaluate the quality of the 4 retrospective analysis studies, the results are shown in Table 2.

Statistical analysis. This study aims to discuss the clinical outcome of IE patients treated with OPAT, further clarify the safety and effectiveness of OPAT for IE patients, and then compare with the previous hospital-based Antibiotic treatment (HBAT). All statistical analyses were performed using the Stata 14.0 software (Stata corporation, College Station, TX, USA) to calculate and analyze the mortality, readmission and relapse rate of IE patients after OPAT treatment. A 95% confidence interval (95% CI) was used to determine the statistical
Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis

W. Wen, et al.
Rev Esp Quimioter 2022;35(4): 370-377

Meta-analysis. Two studies showed low mortality during OPAT, with an ES value of 0.04 (95% CI, 0.01-0.12), and 6 studies which including 976 patients showed low mortality during the follow-up period after OPAT, with an ES value of 0.03 (95% CI, 0.02-0.07). The results of these 8 included studies involving 1062 patients showed that the overall mortality of IE patients treated with OPAT was 0.04 (95% CI, 0.02-0.07), \( P < 0.01 \) (Figure 2A). In addition, 5 studies involving 386 patients was 0.18 (95% CI, 0.08-0.39) during the treatment period, and another 5 studies with 830 patients showed that the readmission rate was 0.14 (95% CI, 0.09-0.22) during the follow-up period.

RESULTS

Characteristics of the included studies. The characteristics of all the included studies are shown in Table 3. A total of 9 studies comprising 1,116 patients were included in this study, of which 5 described mortality, readmission and recurrence rates during OPAT treatment, and 6 described patient outcomes during follow-up.

Table 2
| Study, year [reference] | 1. Was the sample frame appropriate to address the target population? | 2. Were study participants recruited in an appropriate way? | 3. Was the sample size adequate? | 4. Were the study subjects and setting described in detail? | 5. Was data analysis conducted with sufficient coverage of the identified sample? | 6. Were valid methods used for the identification of the condition? | 7. Was the condition measured in a standard, reliable way for all participants? | 8. Appropriate statistical analysis? | 9. Was the response rate adequate? |
|------------------------|-------------------------------------------------|---------------------------------|----------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Durojaiye, 2021 [11]   | Y                                               | N                               | Y              | Y                                              | Y                                                                          | Y                                                                           | Y                                                                           | Y                                                                           | Y                                                                           |
| Partridge, 2012 [14]   | N                                               | N                               | N              | Y                                              | Y                                                                          | Y                                                                           | Y                                                                           | Y                                                                           | Y                                                                           |
| Lacroix, 2014 [16]     | Y                                               | N                               | N              | Y                                              | Y                                                                          | Y                                                                           | Y                                                                           | Y                                                                           | Y                                                                           |
| Amodeo, 2009 [17]      | N                                               | N                               | Y              | Y                                              | Y                                                                          | Y                                                                           | Y                                                                           | Y                                                                           | Y                                                                           |

Y=yes; N=no.

Table 3
| Study, year [reference] | Study design | Treatment period | Follow up period | Total (n) | Adverse events (n) |
|------------------------|--------------|------------------|-----------------|-----------|--------------------|
|                        |              | Mortality (n)    | Relapse (n)     | Readmission (n) | Mortality (n) | Relapse (n)     | Readmission (n) |
| Kortajarena, 2017 [9]  | Cohort Study | -                | -               | 35        | 194               | -               \|
| Pericà, 2019 [10]      | Cohort Study | -                | -               | 33        | 47                | 429             \|
| Durojaiye, 2021 [11]   | Retrospective analysis | -            | 41              | 4         | 8                 | 146             \|
| Htin, 2013 [12]        | Cohort study | 2                | 2               | 3         | 6                 | 68              \|
| Pajarón, 2017 [13]     | Cohort study | 0                | 3               | 6         | -                 | 54              | 11              \|
| Partridge, 2012 [14]   | Retrospective analysis | -            | -               | 1         | 1                 | 44              | 12              \|
| Cervera, 2011 [15]     | Cohort study | -                | -               | 3         | -                 | 12              | 73              \|
| Lacroix, 2014 [16]     | Retrospective analysis | 1            | -               | 6         | -                 | -               | 18              \|
| Amodeo, 2009 [17]      | Retrospective analysis | -            | -               | 10        | 2                 | 5               | 100             | 27              \|

significance of the effect. The results of all studies (effect size (ES) values) were summarized using a random effect model.
Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis

W. Wen, et al.
Rev Esp Quimioter 2022;35(4): 370-377

with an ES value of 0.16 (95% CI, 0.10-0.24) overall (Figure 2B). Regarding the relapse in IE patients, 4 included studies involving 585 patients showed a low overall relapse rate of 0.03 (95% CI, 0.01-0.05), P < 0.01 (Figure 2C).

Regarding the incidence of adverse events in IE patients treated with OPAT, 3 included studies which including 188 patients showed that the incidence of adverse events was 0.26 (95% CI, 0.19-0.33), P < 0.01 (Figure 3). The available data showed that the incidence of adverse events was low in patients treated with OPAT.

Funnel plot analysis showed that there was no particularly significant publication bias in the included literature (Figure 4).

DISCUSSION

A total of 9 studies were included in this study, and the results revealed that OPAT is generally effective and safe for IE patients. The overall mortality rate for patients treated with OPAT was low, namely 0.04 (95% CI, 0.02-0.07). In addition, the overall readmission and relapse rates of IE patients were low, namely 0.16 (95% CI, 0.10-0.24) and 0.03 (95% CI, 0.01-0.05), respectively. Our results are similar to those of previous studies. A study by Htin et al. showed that of 68 patients treated with OPAT, 2 recurred and 2 died, with a one-year survival rate of 96% [12]. Current research data show that OPAT has a good therapeutic effect on IE patients, and it is expected that OPAT will continue to show a good effect in the treatment of IE patients in the future.

OPAT has also shown many benefits, such as providing significant cost effectiveness to inpatient management [1,13,16,19,20], not only by reducing the cost of treatment for patients, but also by bringing benefits to the healthcare delivery system. A study from Europe showed that the use of OPAT therapy for IE reduced costs by approximately €15,000 per patient [16]. Also, Goenaga et al. noted that OPAT reduced the burden of IE on hospital resources, beds and the limited time of health professionals [21]. In addition, outpatient treatment has been shown to reduce hospital-acquired complications, such as hospital-acquired infections, venous thromboembolism, and stress injuries [8,14,15]. Although OPAT has many benefits, the morbidity and mortality of IE and its limited experience in OPAT treatment mean that the candidate patients are selected carefully. Therefore, the mortality and recurrence rate of OPAT may be much lower than that of patients receiving conventional inpatient treatment. The available results showed that OPAT is relatively safe and effective for IE, however, more studies are needed to compare OPAT with routine hospitalization for IE patients (such as HBAT).
Most OPATs follow two main models: First, infusion in the patient’s home, which is called “health care professional outpatient parenteral antimicrobial therapy (H-OPAT)”, with active caregiver intervention. Second, “self-service outpatient parenteral antimicrobial therapy (S-OPAT)”, in which health care personnel initially train patients and/or their caregivers in the use of antimicrobial agents, so the physical presence of healthcare personnel at home during infusion is subsequently unnecessary [13,22]. In the above two modes of OPAT services, the relationship between patients and medical staff is not very close. Although our results showed the effectiveness of OPAT in IE patients and the incidence of adverse events was low, many IE patients still experienced adverse events with an ES value of 0.26 (95%CI, 0.19-0.33). Therefore, it may be necessary to strengthen the monitoring of patients with these two modes of OPAT services. Besides, there is a third type that applies in the case of patients with IE, consisting of a first phase of hospital treatment that gives way to OPAT in a series of very selected patients.

Previous studies have shown that patients treated with OPAT receive less intensive observation than hospitalized patients, and OPAT may increase clinical risk unless there are clear standards and protocols for patient supervision consistent with existing national and international practice guidelines [11,14]. Durojaiye et al. found that pre-existing renal failure and comorbidities (Charlson comorbidity index score) were strongly associated with OPAT treatment failure. Also, patients with a prior history of IE and cardiac complications, such as severe valvular insufficiency, perivalvular abscesses, or internal cardiac fistula, were more likely to have poorer long-term outcomes [11]. Moreover, studies have shown that endocarditis patients with artificial heart valves, consistently positive blood culture results, poorly controlled congestive heart failure, large neoplasms (>10 mm in length), recurrent embolic events, S. aureus etiology, or conduction abnormalities are at increased risk for clinical complications, and therefore inpatient treatment or daily outpatient follow-up during the first 2 weeks of treatment is recommended [22-24]. Andrews et al. recommended that patients with uncomplicated endocarditis caused by viridans group streptococci be discharged from hospital after 1 week to receive OPAT treatment [24]. Therefore, it is very important to select the right IE patients for OPAT at the right time. Furthermore, it is also necessary to strengthen the monitoring and follow-up of IE patients treated with OPAT, including monitoring the patients’ vital signs, complications and relevant laboratory indicators to reduce the occurrence of adverse events. Especially for patients receiving OPAT in the community center or at home, establishing a robust approach to patient monitoring and review is critical [8]. A study has shown that the OPAT Medical Service has established procedures for routine and emergency examination of patients [14]. At Sheffield in the UK, patients are followed up in the OPAT ward at least once a week, this frequent clinical contact facilitates the early detection of complications or clinical deterioration[14], thereby reducing the rate of recurrence and mortality. Finally, it is critical to develop a well-trained OPAT team. Overall, we believe that the benefits of OPAT in the treatment of IE patients outweigh the disadvantages.

This study has some shortcomings. First, we only included English literature, and thus many non-English reports may
be omitted. Second, there was no specific data on
the sex differences, age and underlying diseases of
patients in the included studies, so there was no
subgroup analysis in this respect, and the influence
of these confounding factors on the study results
cannot be excluded. Finally, since not all articles in-
cluded data during OPAT treatment and follow-up
after discharge, it was impossible to compare the
clinical outcomes during treatment and follow-up.
In addition, the data on adverse events of OPAT are
too few, and the number of patients included for
the variable adverse effects is really low, thus more
research data are still needed to confirm the safety
of OPAT.

In general, the mortality, readmission, and re-
lapse rates and incidence of adverse events in IE
patients treated with OPAT are low both during
treatment and follow-up after discharge, indicat-
ing that OPAT is safe and effective for IE patients.
However, our study did not compare routine hospi-
talization as a control group, so conclusions should
be drawn with caution. In order to obtain more sci-
centific and rigorous conclusions and reduce clinical
risks, it is still necessary to expand research in this
field and improve the patient selection criteria for
OPAT service, especially for IE patients, prudent and
selective use of OPAT may produce optimal treat-
ment effects for patients. Finally, clinical monitor-
ing and follow-up of patients treated with OPAT
should be strengthened.

ACKNOWLEDGMENTS

The work was supported by the Key medical
disciplines of Hangzhou.

FUNDING

This study was supported by Hangzhou Science
and Technology Bureau fund (No. 20191203B96;No.
20191203B105;No. 20191231Y039); Youth Fund of
Zhejiang Academy of Medical Sciences (No.
2019Y009); Medical and Technology Project of Zhe-
jiang Province (No. 2020362651, No.2021KY890);
Clinical Research Fund of Zhejiang Medical As-
sociation (No. 2020ZYC-A13); Hangzhou Health
and Family Planning Technology Plan Key Projects
(No.2017ZD02);Hangzhou Medical and Health
Technology Project (No. 0020290592). Zhejiang
Traditional Chinese Medicine Scientific Research
Fund Project(No.20222B280).

CONFLICT OF INTEREST

The authors declare no conflict of interest.
Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis

W. Wen, et al.
Rev Esp Quimioter 2022;35(4): 370-377

REFERENCES

1. Rajaratnam D, Rajaratnam R. Outpatient Antimicrobial Therapy for Infective Endocarditis is Safe. Heart Lung Circ 2021;30(2):207-215. doi: 10.1016/j.hlc.2020.08.016.

2. McDonald JR. Acute infective endocarditis. Infect Dis Clin North Am 2009;23(3):643-64. doi: 10.1016/j.idc.2009.04.013.

3. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169(5):463-73. doi: 10.1001/archinternmed.2008.603.

4. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.

5. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132(15):1435-86. doi: 10.1161/CIR.0000000000000296.

6. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014;148(1):e1-e132. doi: 10.1016/j.jtcs.2014.05.014.

7. Pajarón M, Fernández-Miera MF, Allende I, et al. Self-administered outpatient parenteral antimicrobial therapy (S-OPAT) for infective endocarditis: a safe and effective model. Eur J Intern Med 2015;26(2):131-6. doi: 10.1016/j.ejim.2015.01.001.

8. Seaton RA, Barr DA. Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med 2013;24(7):617-23. doi: 10.1016/j.ejim.2013.03.014.

9. Kortajarena X, Goenaga MA, Ibarguren O, et al. Outpatient parenteral antimicrobial therapy for infective endocarditis in patients over 80 years. Rev Esp Quimioter 2017;30:276-279.

10. Perić S JM, Ulopis J, González-Ramallo V, et al. Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the GAMES cohort. Clin Infect Dis 2019;69(10):1690-1700. doi: 10.1093/cid/ciz030.

11. Duruajaie OC, Morgan R, Chelagha M, et al. Clinical predictors of outcome in patients with infective endocarditis receiving outpatient parenteral antibiotic therapy (OPAT). J Infect 2021;83:644-649. doi: 10.1016/j.jinf.2021.09.021.

12. Htin AK, Friedman ND, Hughes A, et al. Outpatient parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis: a retrospective cohort study. Intern Med J 2013;43(6):700-5. doi: 10.1111/imj.12081.

13. Pajarón M, Lisa M, Fernández-Miera MF, et al. Efficiency of a self-administered outpatient parenteral antimicrobial therapy (s-opat) for infective endocarditis within the context of a shortened hospital admission based on hospital at home program. Hosp Pract (1995) 2017;45:246-252. doi: 10.1080/21548331.2017.1398588.

14. Partridge DG, O’Brien E, Chapman AL. Outpatient parenteral antibiotic therapy for infective endocarditis: a review of 4 years’ experience at a UK centre. Postgrad Med J 2012;88:377-81. doi: 10.1136/postgradmedj-2011-130355.

15. Cervera C, del Río A, García L, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infec Microbiol Clin 2011;29:587-92. doi: 10.1016/j.eimc.2011.05.007.

16. Lacroix A, Revest M, Patrat-Delon S, et al. Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy. Med Mal Infect 2014;44(7):327-30. doi: 10.1016/j.medmal.2014.05.001.

17. Amodeo MR, Clulow T, Laintuch J, et al. Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect 2009;59(6):387-93. doi: 10.1016/j.jinf.2009.09.009.

18. JBI’s critical appraisal tools. Accessed Feb. 14, 2022. Available at: https://jbi.global/critical-appraisal-tools

19. Chapman AL, Dixon S, Andrews D, et al. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 2009;64(6):1316-24. doi: 10.1093/jac/dkp343.

20. Yong C, Fisher DA, Sklar GE, Li SC. A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. Int J Antimicrob Agents 2009;33(1):46-51. doi: 10.1016/j.ijantimicag.2008.07.016.

21. Goenaga MA, Kortajarena X, Ibarguren O, et al. Outpatient parenteral antimicrobial therapy (OPAT) for infectious endocarditis in Spain. Int J Antimicrob Agents 2014;44(1):89-90. doi: 10.1016/j.ijantimicag.2014.04.009.

22. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004;38(12):1651-72. doi: 10.1086/420939.

23. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am 1998;12(4):879-901, vi. doi: 10.1016/S0891-5520(05)70026-x.

24. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis 2001;33(2):203-9. doi: 10.1086/321814. Epub 2001 Jun 20.